Navigation Links
FDA: Breast Implants Basically Safe, But Won't Last a Lifetime
Date:6/22/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, June 22 (HealthDay News) -- Silicone-gel breast implants don't last forever, with as many as half of women with the devices requiring removal within 10 years of the initial surgery, U.S. health officials said Wednesday.

And "the longer a woman has the implants, the more likely she is to experience complications," Dr. Jeffrey Shuren, director for the Center for Devices and Radiological Health at the U.S. Food and Drug Administration, said during a press briefing.

The report released Wednesday said one in five women who receives silicone-gel implants to increase the size of their breasts will need to have these devices removed within 10 years of implant due to complications. And as many as half of women who receive implants for reconstruction after breast surgery will need them removed within the same time frame.

The difference in rates has to do with how much healthy tissue the woman has to support the implants, Shuren explained.

Common complications include: capsular contracture, which is hardening of the area around the implant; the need for additional surgeries; and implant removal. Other frequent problems include implant rupture, wrinkling, breast asymmetry, scarring, pain and infection, the FDA said.

These are basically the same complications noted when the two silicone-gel implants available in the United States were returned to the market in 2006, the FDA said.

Until 2006, silicone-gel implants had been banned by the FDA for 14 years because of concerns about possible links to several diseases, including cancer and lupus.

On Wednesday, Shuren said, "Preliminary data doesn't show an increased risk of breast cancer or connective tissue disease such as rheumatoid arthritis. But to rule those out, we need studies that are larger and longer than those conducted thus far."

The FDA had said recently that breast implants may be linked to a higher risk of a rare form of lymphoma called anaplastic large cell lymphoma, but Shuren noted that those risks are actually "profoundly slim."

The findings announced Wednesday were based on preliminary data from six ongoing post-approval studies conducted by Allergan and Mentor, the two companies that manufacture the silicone-gel breast implants. The studies were mandated by the FDA as a condition of approval back in 2006.

But the companies have acknowledged problems with poor patient follow-up, to monitor their health. The situation is "improving," Shuren said, but wouldn't say what the rate of follow-up is at this point.

The new report concerned only silicone gel-filled implants, not saline implants.

For now, the FDA recommends that women: follow-up regularly with their doctor, which includes occasional MRIs to detect potential ruptures; pay attention to any changes and notify their health-care provider if they notice any unusual symptoms such as pain, asymmetry or swelling; and educate themselves on the signs and symptoms of complications.

Women who have agreed to participate in a study should stay involved.

The implants are safe if "used for the right patient population and the right circumstances, and that is that they are surgically implanted properly and that women continue to have appropriate follow-up," Shuren said.

"If women don't have any symptoms or signs, there's really nothing to do [except follow-up regularly with their doctor]," Shuren said. "At 10 years, most women won't have to take the implant out but, if you need to have it removed, you should have it removed."

According to Shuren, an estimated 5 million to 10 million women worldwide have breast implants.

More FDA advisory panel meetings are planned on the implants.

Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, said the FDA's position that "although silicone breast implants have 'a reasonable assurance of safety . . . the longer a woman has breast implants, the more likely she is to experience local complications or adverse outcomes,' is unquestionably shortsighted as well as contradictory."

"Public Citizen continues to oppose the FDA's 2006 decision to return silicone breast implants to the market for cosmetic use in women for augmentation," Wolfe said in a news release. "The agency's newer information about the risk of implant-associated lymphoma and the previously known risks are serious enough to warrant advising women against having these implanted."

More information

Visit the FDA for more on breast implants.

SOURCES: June 22, 2011, news release, Public Citizen, Washington, D.C.; June 22, 2011, teleconference with Jeffrey Shuren, M.D., director, Center for Devices and Radiological Health, U.S. Food and Drug Administration


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Early Chemical Exposures May Affect Breast Health: Report
2. Shanghai CDC and Hutchinson Center establish Shanghai Breast Health Resource Center
3. Older Women With Breast Cancer Probably Wont Die From It: Study
4. Anti-HIV gel being evaluated in pregnant and breastfeeding women
5. Heart disease beats breast cancer as the biggest killer
6. Roadmap published for dynamic mapping of estrogen signaling in breast cancer
7. FDA Approves Test That Spots Aggressive Breast Cancer
8. FDA Approves Test That Spots HER2-Positive Breast Cancers
9. Breast-feeding May Shield Against Sudden Infant Death Syndrome
10. Signaling pathways point to vulnerability in breast cancer stem cells
11. Einstein scientists find crucial molecule involved in spread of breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Meeting through tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on ... in 26 people will be diagnosed with epilepsy within their lifetime. With such ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... December 05, 2016 , ... Dr. Barry M. Weintraub, one ... Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium at the ... techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is world-renowned for ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... Officer for the Florida Hospital West Florida Region. McGuinness brings experience in executive ... and engaging staff, physicians and leaders. , In her new role, that officially ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  BD (Becton, Dickinson ... global medical technology company, will demonstrate an enhanced technology ... management technologies, including the company,s leading Pyxis™ and Alaris™ ... Pharmacists (ASHP) 2016 Midyear Meeting being held in ... While national data show that approximately 68 ...
(Date:12/5/2016)... Research and Markets has announced the addition of the "Global ... and Demand Forecast to 2022" report to their offering. ... , , ... market is expected to grow at a CAGR of 4.5% during ... witnessing high growth, due to growing female geriatric population and increasing ...
(Date:12/5/2016)... England , December 5, 2016 ... Transitions to Deputy Chairman   ... on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative ... has been appointed as non-executive Chairman, effective January 1 st ... of Mission Therapeutics as a non-executive Director in July 2015. ...
Breaking Medicine Technology: